Morgan Stanley analyst David Lewis maintained a Hold rating on TransMedics Group (TMDX) today and set a price target of $16.00. The company’s shares closed last Friday at $12.90.
According to TipRanks.com, Lewis is a 5-star analyst with an average return of 15.4% and a 70.3% success rate. Lewis covers the Healthcare sector, focusing on stocks such as Axonics Modulation Technologies, Zimmer Biomet Holdings, and Baxter International.
Currently, the analyst consensus on TransMedics Group is a Moderate Buy with an average price target of $19.00.
See today’s analyst top recommended stocks >>
Based on TransMedics Group’s latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $3.39 million and GAAP net loss of $8.5 million. In comparison, last year the company earned revenue of $5.67 million and had a GAAP net loss of $9.2 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
TransMedics Group, Inc. is a commercial stage medical technology company, which engages in the development and commercialization of organ care system platform. It focuses on the preservation of human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation. The company was founded by Waleed H. Hassanein in October 2018 and is headquartered in Andover, MA.